Prospective Electronic Polygenic Risk Study - Second Phase
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age45-65
SponsorScripps Translational Science Institute
About this trial
This study will investigate the role of polygenic risk scores (PRS) in preventive health.
Eligibility criteria
Qualifiers
45 ≥ Age < 65
ASCVD Risk Score > 7.5% as defined by the standard pooled cohort equation
Access to and ability to use a smartphone
Disqualifiers
Prior diagnosis of coronary disease as defined by prior myocardial infarction (STEMI or NSTEMI), or revascularization (stent or coronary artery bypass grafting)
Prior diagnosis or treatment of glaucoma
Cerebrovascular disease with history of ischemic stroke, TIA, carotid endarterectomy, carotid artery stenting
Peripheral arterial disease with history of claudication, revascularization (stents or bypass)
Trial design
Treatments tested in this trial
- Genetic risk assessment
Treatment groups
10,000 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Scripps Translational Science Institute
Lead sponsor
Illumina, Inc.
Collaborator
Optum, Inc.
Collaborator
Quest Diagnostics-Nichols Insitute
Collaborator
Source ClinicalTrials.gov